Alto Neuroscience (NYSE: ANRO) to raise $93.9M in stock sale
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Alto Neuroscience, Inc. entered into an underwriting agreement with BofA Securities, as representative of several underwriters, to issue and sell 3,776,436 shares of common stock in an underwritten registered direct offering under an effective shelf registration statement. The shares are priced at $26.48 per share, and the company estimates net proceeds of approximately $93.9 million after underwriting discounts, commissions and offering expenses.
The closing is expected on July 14, 2026, subject to customary conditions. Alto Neuroscience plans to use the net proceeds, together with existing cash and cash equivalents, to accelerate and expand clinical development of ALTO-207, including a planned additional Phase 3 monotherapy trial in treatment-resistant depression, and for general working capital.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares offered: 3,776,436 shares
Offering price: $26.48 per share
Estimated net proceeds: $93.9 million
+2 more
5 metrics
Shares offered
3,776,436 shares
Common stock in underwritten registered direct offering
Offering price
$26.48 per share
Price per share of common stock in the offering
Estimated net proceeds
$93.9 million
Estimated net proceeds after underwriting discounts, commissions and offering expenses
Expected closing date
July 14, 2026
Expected closing of the underwritten registered direct offering
ALTO-207 trial phase
Phase 3
Additional planned Phase 3 monotherapy trial for treatment-resistant depression
Key Terms
underwritten registered direct offering, shelf registration statement, emerging growth company, treatment-resistant depression, +1 more
5 terms
underwritten registered direct offering financial
"to issue and sell shares in an underwritten registered direct offering"
An underwritten registered direct offering is a way a company raises money by selling newly registered shares or bonds directly to selected investors, with an investment bank agreeing to buy and resell the securities so the company knows it will receive the cash. Think of the bank as a wholesaler that guarantees to take the inventory and find buyers; it speeds the sale but often means the securities are sold at a discount, which can dilute existing shareholders and affect the stock price.
shelf registration statement regulatory
"pursuant to an effective shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
emerging growth company regulatory
"The company qualifies as an emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
treatment-resistant depression medical
"Phase 3 trial of ALTO-207 as monotherapy for treatment-resistant depression"
A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.
Phase 3 trial medical
"to conduct an additional planned Phase 3 trial of ALTO-207"
A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.
FAQ
What equity offering did Alto Neuroscience (ANRO) announce?
Alto Neuroscience entered into an underwriting agreement to issue and sell 3,776,436 shares of common stock in an underwritten registered direct offering under an effective Form S-3 shelf registration statement, with BofA Securities acting as representative of the several underwriters.
How much capital will Alto Neuroscience (ANRO) receive and at what price?
Alto Neuroscience is offering its common stock at $26.48 per share and estimates approximately $93.9 million in net proceeds after underwriting discounts, commissions and offering expenses, based on the agreed share count in the underwritten registered direct offering.
When is the Alto Neuroscience (ANRO) stock offering expected to close?
The offering is expected to close on July 14, 2026, subject to customary closing conditions. Completion depends on those conditions being satisfied, consistent with standard practice for underwritten offerings managed by the appointed underwriters and co-managers.
How will Alto Neuroscience (ANRO) use the net proceeds from this offering?
Alto Neuroscience intends to use the net proceeds, together with existing cash and cash equivalents, to accelerate and expand clinical development of ALTO-207, including a planned additional Phase 3 monotherapy trial in treatment-resistant depression, and for general working capital purposes.
Who are the underwriters and managers for Alto Neuroscience (ANRO)'s offering?
BofA Securities, Stifel, William Blair and Baird are joint book-running managers for the offering, while JonesTrading and H.C. Wainwright serve as co-managers. BofA Securities acts as representative of the several underwriters named in the underwriting agreement.